Funding Opportunity for Clinical Stage Projects
Max Award
First in Human (For-Profit):
$8,000,000
First in Human (Non-Profit):
$12,000,000
Phase 2, Phase 3, and Pivotal:
$15,000,000
Duration
Project period
Award Cycles
Recurring
Anticipated Awards
per Fiscal Year
Page Contents
Summary
The California Institute for Regenerative Medicine’s (CIRM’s) Clinical Stage Funding Program supports completion of an interventional phase 1, 2, or 3 trial (including pivotal trials)—along with any essential lead-in or natural history studies—under a single FDA-cleared protocol. Projects should be part of a broader clinical development plan aimed at marketing approval and include strategies for equitable patient access, representative enrollment, and responsible pre-commercialization.
CIRM’s investment extends beyond funding. Awardees form a partnership with CIRM’s internal teams and external experts to advance the program with rigor, transparency, and efficiency. Applications are evaluated using guiding principles, which emphasize transformative patient impact, solutions to access barriers, and a portfolio that serves both prevalent and rare diseases.
Potential Applicants can use the navigation to locate detailed information about the program, including its background, objective, scope and structure, eligibility requirements, Application preparation and review, Award administration, and resources and contact information.
Background
Through the Clinical Stage Funding Program (CLIN2), CIRM creates funding opportunities for the types and stages of Clinical Research that otherwise do not exist or are of limited scope and focus to advance the field of regenerative medicine. The CLIN2 program is a part of CIRM’s core product development programs that unlike other funding sources, provide reliable and predictable funding throughout the Project Period.
Objective
The objective of this funding opportunity is to support the completion of an interventional phase 1, 2, or 3 trial (including pivotal trials) as defined by a single FDA-cleared clinical protocol, for an innovative stem cell-based or genetic therapy addressing a serious unmet need and with the potential for transformative benefits to patients, families and the health care system. In addition to the interventional trial, the program may also support a lead-in normal healthy volunteer study or natural history study that is needed for baseline or control data for the interventional trial. The trial should be part of a clinical development program aiming for marketing approval and which proposes stage-appropriate pre-commercialization activities, including development of a patient access strategy. The clinical development program for the supported trial should demonstrate a commitment to enrolling a patient population reflective of the demographics of the disease population. Further, the clinical development program should leverage CIRM-funded and externally funded infrastructure for data, resource or knowledge sharing to drive rigor, efficiency, and transparency of clinical trial results.
Under this program, CIRM will act not only as a funding agency, but will also devote significant internal resources and leverage its external team of world-class subject matter experts to actively advance the project. The result of a successful Application will be the formation of a true partnership that both accelerates the program and gives it the greatest opportunity for success.
Program guiding principles
Guiding principles describe how CIRM translates its funding priorities and Strategic Allocation Framework recommendations into desired portfolio outcomes. Principles shape program objectives, inform the criteria by which projects are selected by the Grants Working Group (GWG) for discussion and recommendations, and inform the recommendations that CIRM teams bring to the Application Review Subcommittee (ARS) to support funding decisions.
To achieve the objective of this program, guiding principles will prioritize projects that contribute to a portfolio designed to:
- Offer transformative impact for patients, meaning therapies that provide significant benefits over existing therapies and therapies in clinical trials;
- Address known barriers to access of stem cell-based and genetic therapies, and;
- Broadly address both prevalent and rare diseases affecting Californians.
The guiding principles are applied throughout the Application lifecycle to ensure the development of a scientifically meritorious portfolio aligned with CIRM’s strategic goals.
Scope and Structure
The CLIN2 Award supports completion of an interventional phase 1, 2, or 3 clinical trial for a stem-cell based or genetic therapeutic candidate and may also fund an associated natural-history comparator or lead-in normal healthy volunteer study. Applicants are encouraged to use accelerating trial designs where appropriate, such as basket trials or adaptive design dose-escalation protocols.
Program activities
Applicants may request funding for activities conducted in California or outside California, subject to the applicable requirements and limitations for California and non-California Organizations described under “What should one know before preparing the budget?”
CIRM will fund the following activities under this opportunity:
Required activities
- All clinical operations activities needed to complete the trial within the 4-year Award period
- Outreach, enrollment, and retention activities to achieve trial enrollment demographics reflecting the target patient population
- Treatment of patients with the therapeutic candidate (or control) and follow-up visits per the clinical protocol
- Sharing of any non-clinical as well as clinical data per the CIRM data sharing requirements
- Establishment and regular convening of a Strategic Planning Committee (SPC) with clinical development expertise to provide forward-looking strategic advice
- Activities associated with patient access strategy and planning for the therapeutic candidate in the proposed indication
- Activities associated with managing, preserving, and sharing data and knowledge from the study
Allowable activities
- Natural history studies needed for baseline or control data for the interventional trial
- Lead-in studies in normal healthy volunteers for the interventional trial[1]
- Studies to develop biomarkers, understand mechanisms of action and develop a potency assay
- Regulatory activities including FDA interactions and requests for designations
- Non-clinical studies required by the FDA (FDA documentation required)
- Strategic planning activities
- Manufacturing activities to supply the current clinical trial, including technology transfer and FDA-approved comparability studies, if needed
Conditionally allowable activity
- Manufacturing for the next phase trial. Funding of that activity will be conditioned on 1) an interim evaluation by CIRM and a panel of independent experts of the clinical trial data to date, and 2) provision of 50% Co-Funding for this activity, if Co-Funding is required as specified in “Award amount and duration” below
Unallowable activities
CIRM funds cannot be used to support the following activities under this opportunity:
- Costs incurred on or before the date of the Independent Citizens’ Oversight Committee (ICOC) approval
- Discovery or translational research
- Activities already budgeted or paid for under a prior, existing or future CIRM Award
- Clinical Research carried out under an Investigational Device Exemption (IDE)
- The costs of activities performed by a separate out-of-state organization that retains intellectual property or independent publication rights in any intellectual property (e.g., invention, technology, data) arising out of the CIRM-Funded Project
Award amount and duration
Stage | Max Award Amount |
First in Human[2] | $8,000,000 (For-Profit Organizations); $12,000,000 (Non-Profit Organizations) |
Phase 2 or Subsequent[3] | $15,000,000 |
Phase 3 or Pivotal | $15,000,000 |
The maximum Award duration is four years. The requested amount must be adequately justified and is subject to adjustments prior to the issuance of an Award based on assessments of the Grants Working Group (GWG), the CIRM team, or by the Application Review Subcommittee (ARS) of the Independent Citizens’ Oversight Committee (ICOC).
Funding allocation
CIRM anticipates making 9-16 CLIN2 Awards per year, contingent on the number of Applications at each funding level that are recommended.
Provisional timetable
CLIN2 funding opportunities will recur four times per year. The anticipated timeline of each funding cycle is as follows:
Date | Provisional Timetable |
Applications Open | Four times per year |
Applications Due | Please visit Funding Opportunities on the CIRM website for current Application deadlines |
Grants Working Group Selection | Approximately 60 days after Application deadline |
Grants Working Group Discussion | Approximately 30 days after Grants Working Group Selection |
Application Review Subcommittee Award Approval | Next available Application Review Subcommittee meeting after Grants Working Group Discussion |
Award Start | Must be prepared to commence Award activities within 60 days of Award approval. See Eligibility Criterion #8 for further details |
[1] Studies in normal healthy volunteers must be part of the same approved protocol as the interventional study.
[2] For this Program Announcement, a trial is considered First-in-Human if it is the first clinical trial using this therapeutic candidate in the proposed disease indication and using a given route of administration.
[3] For this Program Announcement, “Subsequent” trials are any phase 1 trials following a First-In-Human trial in the proposed disease indication and using a given route of administration. This definition excludes phase 3 or pivotal phase 2 trials.
Eligibility
All the following requirements must be fully satisfied for an Application to be accepted and considered for funding by CIRM. Refer to CIRM Award Management Policy (AMP) and CIRM Funding Opportunities: Common Requirements and Definitions for a list of definitions and requirements.
Critical Role and Effort Requirements
Critical Role* | Minimum Percent Effort |
Principal Investigator | 15% |
Project manager | 50% |
*Review CIRM’s Award Management Policy for the definition and requirements of “Critical Role.”
Key Personnel with Required Expertise
Key Personnel* | Required Expertise |
Data Project Manager | Demonstrated experience in data handling. See CIRM Common Requirements and Definitions for full definition. |
*Review CIRM’s Award Management Policy for the definition and requirements of “Key Personnel.” Expertise requirements listed for Key Personnel can be fulfilled by one or more individuals on the Applicant team.
(1) The Applicant must propose an interventional phase 1, 2, or 3 clinical trial for a stem cell-based or genetic therapy.
Refer to CIRM Funding Opportunities: Common Requirements and Definitions for definitions of stem cell-based or genetic therapies in scope for the CLIN2 program. The overall project and proposed activities must fall within the defined scope of this opportunity. Stem cell-based or genetic therapies being developed under INDs are eligible. Therapeutic devices developed under IDEs are ineligible.
(2) The Applicant must meet readiness criteria at the time of Application.
For projects not progressing from a CIRM preclinical stage Award, the IND application and clinical protocol must be cleared by FDA at the time the CIRM Application is submitted. The clinical protocol submitted with the Application must be the latest version that will be used to conduct the trial. For projects progressing directly from a CIRM preclinical stage or earlier phase clinical trial Award, the IND application must have been submitted to FDA by the time of the CLIN2 Application and must be cleared to proceed within 30 days of the CLIN2 Application submission. Direct progression occurs when a prior CLIN2, CLIN1, PDEV, or TRAN1 Award addressed the same indication with the same therapeutic, and the last activity or objective of that prior Award aligns with the start of the current Application.
(3) The Principal Investigator (PI) must commit a minimum of 15% effort and adhere to CIRM’s requirements.
The PI must commit a level of effort on the project consistent with achieving the CLIN2 program objective and not less than 15% on average over the Project Period. The PI must adhere to general eligibility requirements described in CIRM’s Award Management Policy and CIRM Funding Opportunities: Common Requirements and Definitions.
(4) The project team must include an experienced project manager who commits at least 50% effort.
The project team must include a project manager with experience in managing relevant clinical development projects. The project manager should be familiar with and utilize a variety of processes and tools to manage team communication, team dynamics, project budget, project schedule, project resources and project risks to help their team achieve the project objective in a timely manner. The project manager must commit at least 50% effort on average over the Project Period.
(5) The project team must include an experienced Data Project Manager.
To ensure effective and collaborative sharing and management of data, a Data Project Manager must be part of the team. This individual must have demonstrated experience in data handling and is responsible for interfacing with a data management team(s), interfacing with CIRM’s planned data infrastructure, reporting progress on data management and sharing as well as maintaining the integrity of data during ingestion. The Data Project Manager role can be fulfilled by one or more individuals on the Applicant team.
(6) The CIRM Applicant must be the IND sponsor.
The IND sponsor (i.e., the entity named as the sponsor on the IND) for the proposed therapeutic must be the CIRM Applicant (if an organization-sponsored IND) or the CIRM Principal Investigator (if an investigator-sponsored IND).
(7) The Applicant must have at least one trial site located in California.
Applicants located outside of California must have at least one clinical site in California.
California Applicants must have at least one clinical trial site in California and must provide justification for inclusion of any sites located outside the State. Applicants are strongly encouraged to use CIRM Clinical Network sites when feasible.
(8) The Applicant must be ready to initiate work on the funded project within 60 days of approval.
Given the urgency of CIRM’s mission, all approved Awardees must initiate work on the CIRM-Funded Project within 60 days of approval and authorization for funding by the Application Review Subcommittee of CIRM’s governing board, the Independent Citizens’ Oversight Committee (ICOC).
Because of the open and ongoing nature of this Program Announcement, investigators should only apply when their project has reached the stage where all eligibility criteria are met. CIRM reserves the right to refuse to consider an Application that is submitted prior to the completion of all necessary prerequisites.
(9) The Application must be accurate and complete.
All required components of the Application must be completed and may not contain false or inaccurate information.
(10) The Applicant must propose appropriate Co-Funding and demonstrate availability of funds.
CIRM will require Co-Funding as specified in the table below, based on the total “allowable project costs.”
Co-Funding requirements
Organization Type | First in Human | Phase 2 or Subsequent | Phase 3 or pivotal | Manufacturing for next trial |
Non-Profit | None | None | 50% | 50%, if overall Award has a Co-Funding requirement |
Non-Profit with For-Profit Partner | 30% | 50% | 50% | |
For-Profit | 30% | 50% | 50% | |
The Co-Funding requirements for a For-Profit Applicant also apply to Non-Profit Applicants with For-Profit Partners. Visit CIRM Funding Opportunities: Common Requirements and Definitions for CIRM’s definition of a “Partner.” Co-Funding requirements will be based on trial stage and partnership status at the time of Application. Applicants must declare whether they have a Partner in their CLIN2 Application. Non-Profit Applicants without a For-Profit Partner applying for funding for trials that are not phase 3 or pivotal may provide Co-Funding, but it is only required when project costs are more than the maximum CIRM Award amount. Please see the Allowable Costs and Co-Funding FAQ for more information about Co-Funding requirements.
Applicants must also demonstrate, by the Application deadline, a commitment of funds from other sources for non-allowable project activities that are necessary to achieve the goals of the Application. Allowable project costs for research funded by CIRM are detailed in CIRM’s Award Management Policy and include direct, facilities, and Indirect Costs. The sum of CIRM funds requested plus the Co-Funding contribution by the Applicant make up the total allowable project costs. Only funds that will be spent concurrently with CIRM funds (i.e., no sooner than board approval and no later than completion of the final Operational Milestone) will qualify toward this Co-Funding requirement.
Description and documentation demonstrating the commitment of funds to cover the proposed Co-Funding amount must be provided as part of the Application and by the Application deadline. The Co-Funding may come from any funding source arranged by the Applicant but may not include “in-kind” or similar types of support. The Applicant may propose to use cash-on-hand, committed funding and/or planned fundraising as sources of funds for the Co-Funding commitment but must demonstrate that it will have cash-on-hand at project start date corresponding to at least 25% of the total Co-Funding amount required by the Award.
Alternatively, For-Profit Applicants and For-Profit Partners of Non-Profit Applicants may elect to fulfill all or a portion of the minimum Co-Funding requirement through CIRM’s SAFE-based Co-Funding program. Under this option, the Applicant or For-Profit Partner agrees to issue a Simple Agreement for Future Equity (SAFE) to CIRM. Applicants electing SAFE-based Co-Funding may request additional CIRM funding to cover the applicable Co-Funding commitment, up to the maximum CIRM Award amount. Any portion of the required Co-Funding that cannot be satisfied through the SAFE-based Co-Funding program must be provided in cash. Applicants electing this option must submit an executed SAFE Term Sheet with their Application and execute the definitive SAFE agreement prior to the start of the Award. Applicants are advised to contact legal@cirm.ca.gov for additional guidance and information on SAFE-based Co-Funding.
(11) For-Profit Organizations must demonstrate Solvency.
Solvency requirements are defined in CIRM Funding Opportunities: Common Requirements and Definitions.
(12) The Applicant must be in “Good Standing.”
Applicants and their Affiliates must represent and certify that they are in Good Standing, as described in CIRM Funding Opportunities: Common Requirements and Definitions.
Application Preparation
Consultations
Consultations are required for this program. CIRM Science Officers hold consultations to address questions about their project’s eligibility or other project-specific questions.
Webinars
CIRM staff aims to conduct public webinar(s) and Q&A sessions after posting of this Program Announcement. Prospective Applicants are encouraged to sign up for email alerts and register for these sessions on our website.
How does one submit an Application?
Applications must be completed and submitted online using the CIRM Grants Management System. A prospective PI must create a login in the system to open an Application and submit materials. Applications are available in the system to the PI or their approved delegate. Organizations that have not previously applied for CIRM funding should designate a provisional Authorized Organizational Official (AOO) in the Application and must request verification of that individual prior to submission. Please reference CIRM’s Guide for AOOs for more information regarding this role. A PI may submit only one CLIN2 Application per review cycle.
What components does an Application include?
CIRM’s online Application is designed to collect information for CIRM staff to assess eligibility, for Grants Working Group reviewers to evaluate the project, and for CIRM rapidly to initiate an Award if the project is approved for funding.
In the online Application, Applicants must fill out an eligibility form, indicate Key Personnel involved in the project, provide a list of Consultants and Subcontracts, provide an overview of proposed activities, and prepare and justify an appropriate budget. In addition, Applicants must certify that appropriate institutional approvals (e.g., SCRO, IACUC or IRB) will be in place during the Award.
The document uploads page provides templates for the Scientific Proposal, Patient Access Proposal, candidate eligibility information, biosketches, financial Solvency and Co-Funding information, and other funding support information. Applicants must use the provided templates. In addition, the uploads page provides links for uploading the clinical protocol, FDA correspondence, the manufacturing plan, investigator brochure, intellectual property plan and quotes to support the budget.
What are the contents of the Scientific Proposal?
The Scientific Proposal comprises the bulk of detailed information on the project, organized within the following sections. Page limits and formatting information will be provided on the Proposal template.
- Project summary: A high-level summary of the project.
- Target product profile: Template-based product label containing base case and optimal specifications for the proposed product.
- Value proposition: Description of the unmet need, standard of care, affected patient population, competitive landscape, and the therapy’s potential value (health and financial) for patients, families, caregivers and the healthcare system.
- Scientific rationale: Description of the proposed product and scientific data supporting use of that product as a therapy for the target indication.
- Preclinical studies: Template-based tabular summary of key preclinical studies, including IND-enabling study results.
- Clinical studies: Template-based tabular summary of completed or ongoing clinical studies with the proposed or a related product.
- Gantt-Like timeline: Timeline with monthly granularity for all major activities, including activities described in the Patient Access Proposal.
- Project plan: Description of all proposed activities detailing how the objective of the Program Announcement will be met.
- FDA correspondence: Template-based tabular high-level summary of regulatory requests and proposed action plans.
- Manufacturing plan synopsis: Template-based synopsis describing key aspects of the manufacturing plan for the proposed trial.
- Clinical protocol synopsis: Template-based synopsis describing key aspects of the protocol for the proposed trial.
- Clinical operations plan:
- Template-based synopsis describing key aspects of the planned clinical operations for the proposed trial with emphasis on how this plan supports the feasibility of meeting the patient enrollment timelines.
- Description of the population impacted by the indication. Description of proposed study sites for the trial and plans to leverage study site and other resources for outreach to and enrollment of affected patient populations. Description of plans to address barriers to participation faced by affected patient populations.
- Target Enrollment Table listing the planned number of trial participants and a rationale for enrollment targets.
- Patient Access and Commercialization Strategy: A detailed description of the overall clinical development strategy and patient access strategy for the proposed therapeutic. Description of how patient access priorities inform the design, development and delivery of the proposed therapy in the target indication. Descriptions of completed, in-progress and planned stage-appropriate patient access, market access and commercialization activities consistent with CIRM’s Patient Access Planning Requirements.
- Data sharing overview: A detailed description of how raw data, processed data and metadata produced from the project will be made available to the research community consistent with FAIR (Findability, Accessibility, Interoperability, and Reusability) data sharing principles. Refer to CIRM Data Sharing and Management for additional information on how Applicants should address data sharing and how the data sharing overview will be evaluated. The requirements described in CIRM Data Sharing and Management are incorporated here by reference.
- Team organization: Qualifications of the Principal Investigator and Key Personnel representing all critical functions of the project.
- Plans for risk mitigation and financial contingency: Project risks, mitigation strategies, contingency plans, associated costs, and non-CIRM sources of Contingency Funds.
- Resources and project environment: Institutional offerings that will benefit the project.
- References: Sources cited in the proposal.
What should one know about CIRM’s requirements for patient access planning?
Successful and timely access to approved stem cell-based and genetic therapies requires stage-appropriate strategic planning throughout preclinical and clinical stages of development to ensure that the therapy is accessible to the affected patient populations. To help ensure that projects are adequately preparing for patient access, CIRM has developed a roadmap and associated requirements for stage-appropriate strategic planning activities in preclinical and clinical development funding programs. Applicants must review the Patient Access Planning Requirements resource document for stage-appropriate patient access, market access, and commercialization activities applicable to the proposed trial stage. These include both prerequisite activities (which must be completed by the time of Application submission) and activities which must be proposed during the Award period. Applicants must adequately describe progress to date and propose a plan for completing applicable stage-appropriate activities as part of the CLIN2 Application. Proposed patient access planning activities will be incorporated into CLIN2 Award Operational Milestones. Awardees will also be required to report progress on applicable commercialization and market access activities over the course of the CLIN2 Award.
What should one know before preparing the budget?
The total CIRM Award is subject to a total Award cost cap of allowable project costs. Allowable project costs are those costs permitted under CIRM policies and regulations and include direct, Facilities, and Indirect Costs. CIRM will not fund costs that exceed the specified Award amount, and Applicants are expected to justify their budgets within these limits, inclusive of cost-sharing from the Applicant or third parties.
Budgets must be justified in detail, including all Subcontracts and Consultant fees, including, if applicable, any additional costs that would be funded from another source. Allowable project costs for research funded by CIRM are detailed in the CIRM Award Management Policy (AMP). Generally, project costs for personnel, supplies, travel, Equipment, data sharing/management and Subcontracts may be claimed. Requests to purchase Equipment will be reviewed and subject to approval by CIRM during pre-funding administrative review (PFAR) or via a Prior Approval Request (PAR) during the Project Period. Limits for specific cost categories must be observed.
CIRM makes no prior stipulations on how funds are distributed among the Principal Investigator and Co-Investigators in the team. However, specific budget allocations for each member of the team (PI and Co-Investigators) must be delineated in the budget justification and should reflect relative contributions and project needs. This aspect of the budget will be subject to evaluation by the Grants Working Group.
For a California Organization, allowable project costs include:
- The per subject share of the costs of Clinical and non-Clinical Research activities that are directly attributable to the treatment of subjects enrolled in the proposed clinical trial; and
- Costs of manufacturing activities for a subsequent clinical trial, contingent on 1) an interim evaluation by CIRM and a panel of independent experts of the clinical trial data to date, and 2) provision of 50% Co-Funding for this activity, if Co-Funding is required for the overall Award (see CLIN2 Co-Funding Requirements table above).
For a non-California organization, allowable project costs include:
- The per subject share of the costs of Clinical and non-Clinical Research activities, whether conducted in California or outside of California, that are directly attributable to the treatment of California subjects enrolled in the proposed clinical trial; and
- Costs of manufacturing conducted in California for the proposed clinical trial for subjects enrolled, provided such costs are deducted before calculating the per subject share of costs; and
- Costs of manufacturing conducted in California for a subsequent clinical trial contingent on 1) an interim evaluation by CIRM and a panel of independent experts of the clinical trial data to date, and 2) provision of 50% Co-Funding for this activity, if Co-Funding is required for the overall Award (see CLIN2 Co-Funding Requirements table above).
Unallowable costs
- The costs of activities performed by a separate out-of-state organization that retains intellectual property or independent publication rights in any intellectual property (e.g., invention, technology, data) arising out of the CIRM-Funded Project.
- For a non-California Applicant, the per subject share of the costs of Clinical and non-Clinical Research activities, whether conducted in California or outside of California, that are NOT directly attributable to the treatment of California subjects enrolled in the proposed clinical trial.
For any proposed Subcontracts over $500,000, a tabulated summary of at least three proposals must be provided, and the selection of the Subcontractor must be justified in detail. If any such Subcontracts are sole sourced, detailed justification must be provided. The “Resources” section of this PA describes available resources for CIRM-Funded Projects including the CIRM Clinical Network, the CIRM academic GMP Manufacturing Network and the CIRM Industry Resource Partners composed of reagent, equipment and service providers (i.e., CDMOs, CROs, etc.).
What are direct facilities costs and how much can an Applicant claim?
Direct facilities costs are the general operating costs of the Awardee’s facilities attributable to housing all elements of the CIRM-Funded Project or Activity. Facilities costs for Non-Profit Applicants are limited to the current applicable, federally negotiated rates for the organization as defined by the Office of Management and Budget (OMB) Circular A-21 or A-122. Facilities costs for For-Profit Awardees or any Non-Profit Awardees without a federally negotiated Facilities and Administrative Rate agreement are limited to 15% of direct project costs and must be consistent with facilities rates applied to similar research Awards at the organization. Facilities rates are applied to direct project costs exclusive of the costs of Equipment, Tuition and Fees, Research Patient Care Costs, and the total cost of each individual Subcontract, Consultant and service agreement in excess of $50,000. The facilities cost rates approved and in place at the time of the Application are to be applied to the entire Project Period.
What are Indirect Costs and how much can an Applicant claim?
Indirect Costs are defined in CIRM’s Award Management Policy as administrative costs of the Awardee incurred for common or joint objectives, which cannot be readily and specifically identified with a particular project. For-Profit Organizations cannot claim Indirect Costs. For Non-Profit Organizations, Indirect Costs will be limited to 20% of allowable Direct Research Funding Costs awarded by CIRM (i.e., project costs and facilities costs), exclusive of the costs of Equipment, Tuition and Fees, Research Patient Care Costs, as well as the costs of each individual Subcontract, Consultant and service agreement in excess of $50,000. The Indirect Cost rate budgeted at the time of Application is to be applied to the entire Project Period.
Change in status
Applicants are required to notify CIRM of any material change in status while the Application is pending review (e.g., a change in PI, the Applicant no longer qualifies as a California Organization, etc.).
Application Review Information
What is the process for evaluating an Application?
Eligibility and completeness review
CIRM will assess whether the proposed project meets eligibility requirements sought under this program. If CIRM determines, in its sole discretion, that an Application does not meet the eligibility requirements of the program or that the submitted Application is incomplete or contains false or inaccurate information, CIRM will notify the Applicant of its decision and, if CIRM deems it appropriate, allow an opportunity for the Applicant to remedy the deficiencies. If CIRM deems it inappropriate, or if the Applicant does not remedy the error in a timely manner, CIRM will terminate all further action on the Application.
CIRM may exercise its authority to make eligibility determinations at any time before an Award is executed.
Grants Working Group Application selection
If the number of Applications submitted exceeds the volume that can reasonably be reviewed by the Grants Working Group (GWG) panel, the GWG will conduct an initial screening to identify those Applications that best align with the CLIN2 Awards objectives based on the criteria listed below. Applications will receive a composite score, which combines two measurements from the GWG reviewers, selection and rank. The two measurements are weighted 60% and 40% respectively. A composite score cut-off will be established at the closest numerical break to the target number of Applications which will proceed to GWG discussion.
Reviewers may provide brief comments or categorical assessments at this stage; however, detailed feedback to Applicants is not guaranteed.
The selection criteria for Clinical Stage Funding (CLIN2) Applications are:
- The therapy’s potential to provide a meaningful and significant improvement in clinical outcomes compared to therapies currently available or in development.
- Impact of addressing the unmet medical need on patients, caregivers and the healthcare system.
- Feasibility and practicality of the therapy’s uptake by patients, caregivers, and the healthcare system.
The CIRM President and CEO, upon recommendation from CIRM scientific staff, may advance a limited number of additional Applications not selected by the GWG if there is a compelling programmatic justification.
Grants Working Group discussion and recommendations
The scientific merit of each Application that is selected for full review will be assessed by the Grants Working Group (GWG), which is composed of fifteen subject matter experts from outside California, seven patient advocate or nurse members of the Independent Citizens’ Oversight Committee (ICOC) (called “GWG Board Members”), and the Chair of the ICOC. Information about the bylaws of the GWG and a list of scientific members who may participate in the GWG review can be found at Our Working Groups page. The composition of the ICOC can be viewed on Our Governing Board page.
The fifteen participating scientists on the GWG will evaluate the Applications and score them on a scale of 1-100 according to scientific and technical merit, applying the review criteria described below. For purposes of making funding recommendations to CIRM’s board, each Application will be assigned to one of two categories based on the median score as follows:
Median score 85 or above: The Application has exceptional merit and warrants funding, if funds are available; or
Median score below 85: The Application is not recommended for funding.
The Application Review Subcommittee (ARS) of the Independent Citizens’ Oversight Committee (ICOC) will make final funding decisions.
Patient advocate and nurse members of the GWG will also evaluate the Applications and provide a separate Patient Perspective Score on a scale of 1-5 (with 5 being the best possible score), applying the patient perspective review criteria described below. The overall funding recommendation by the GWG is determined only by the scientific score. However, the patient perspective score may inform and influence the scientific score during the GWG discussion and may also impact the review by the Application Review Subcommittee (ARS) of the ICOC, which makes the final funding decisions.
Budget review
CIRM will review the proposed budget to ensure all costs are reasonable, allocable, consistently treated and allowable. CIRM may adjust the budget prior to issuance of an Award based upon assessments of the Grants Working Group, the CIRM team, or by the Application Review Subcommittee (ARS) of the Independent Citizens’ Oversight Committee (ICOC).
Consideration of past CIRM Award information (if applicable)
The Grants Working Group (GWG) may consider information from a previously funded and related CIRM Award as part of its review. CIRM will provide the GWG with objective information regarding a related Award that CIRM, in its sole discretion, deems relevant, including but not limited to achievement of specific milestones, data, and outcomes for a related CIRM Award or Awards.
A “related CIRM Award” includes: (1) an Award for which the Applicant PI served as the PI, a Co-PI, a Co-Investigator, or otherwise substantially participated in the conduct of the Award; (2) an Award involving the same research project or product; or (3) an Award that includes overlapping team members.
Confidentiality
CIRM’s confidentiality and conflict screening rules apply to everyone who will have access to Applications or who will attend any review meeting in which confidential information is discussed, including but not limited to CIRM team members, reviewers, experts providing input to reviewers, and members of the Independent Citizens’ Oversight Committee (ICOC).
How will the scientific merit of an Application be evaluated?
1. Value proposition – Evaluate the extent to which the therapy offers a compelling value proposition based on holistic consideration of the following:
- Assess the therapy’s potential to provide a meaningful and significant improvement in clinical outcomes for the intended population as compared to therapies currently available or in trials (e.g., efficacy, safety, patient burden).
- Assess the expected impact of addressing the unmet medical need on patients, caregivers, and the healthcare system.
- Evaluate the feasibility and practicality of the therapy’s uptake by patients, caregivers, and the healthcare system.
- Assess whether the Applicant has proposed a stage-appropriate strategy for enabling access to the proposed therapy for the intended patient population.
2. Rationale – Evaluate the scientific rationale for the proposed therapy and the strength of the supporting data
- Assess the fundamental robustness of the scientific rationale including justification for the indication, therapeutic approach, regimen and route of administration.
- Assess the extent to which the rationale for clinical development of the proposed therapy is supported by the body of available data, including compelling evidence of disease modifying activity in relevant disease models and any available clinical trial data generated using the proposed therapeutic approach.
- Consider the strengths and limitations of the data presented and/or the models utilized in completed studies.
3. Project plan and design – Evaluate the project’s plan and design
- Evaluate the extent to which the proposed activities are necessary and appropriate to efficiently and effectively drive clinical development of the proposed therapy. For example, the Applicant should consider:
- whether the project will generate data to enable stage appropriate go/no-go decision making for further investment in the approach;
- the feasibility of achieving timely full enrollment of the trial; and
- the appropriateness of the manufacturing process, plan and analytical development plans.
- Consider whether the project’s objective is likely to be achieved within the proposed budget and timeline.
- Assess the validity of the potential project risks identified and contingency plans presented.
4. Project team and resources – Evaluate the expertise and resources that will be deployed to achieve the project deliverables
- Evaluate the appropriateness of the team’s leadership, expertise and staffing to successfully complete all aspects of the project.
- Consider whether a robust plan for coordination and execution of the project has been clearly outlined.
- Assess the extent to which the team has access to all the necessary resources and facilities, including manufacturing facilities, to successfully conduct the proposed activities.
- Consider whether the collective team, including Consultants and Subcontractors, have a demonstrated track record of supporting stem cell-based and genetic therapy projects through clinical trials and/or towards licensure, as stage-appropriate.
5. Population impact – Evaluate the extent to which the project considers the potential impact of the proposed therapy across affected populations
- Evaluate the Applicant’s understanding and consideration of the affected population for the target indication, including any differences in detection/diagnosis, disease burden, care, and health outcomes across the affected population.
- Assess the appropriateness of the proposed trial study population in the context of current knowledge of demographic groups at risk for the target indication.
- Consider the Applicant’s goals to achieve a comprehensive distribution of subjects appropriate to the proposed indication and whether key criteria to disqualify any at-risk groups are justified.
- Evaluate the extent to which the Applicant’s plan for participant outreach, engagement, enrollment and retention addresses key barriers to trial participation by all affected population groups, is well-matched to the proposed study population and is feasible in the proposed time frame.
How will the Patient Perspective Score be determined?
Patient advocate and nurse members of the GWG will evaluate and score Applications using the following criteria:
- Relevance: Does the project address a real and significant problem for patients?
- Patient Benefit: If successful, would the therapy make a meaningful difference to patients?
- Patient Centered: Is the proposal designed with the affected patient population in mind?
- Patient Engagement: Is the patient perspective included and used to inform therapeutic objectives?
- California Benefit: How beneficial will the therapy be for people in California?
Award Administration
Issuance of Award
CIRM issues Awards through a Notice of Award (NOA), which serves as the official contract defining terms, conditions, and funding commitments. Before finalizing the NOA, CIRM reserves the right to modify project activities and budgets, including improving data sharing plans submitted during pre-funding administrative review. After consulting with project teams, CIRM establishes milestones, success criteria, and timelines based on Application information and data sharing plans and may consult external advisors when developing Operational Milestones for research, data sharing, and access planning activities. CIRM will also review key agreements critical to project success to ensure compliance with applicable policies and regulations.
Operational Milestones and payment
CIRM funds under the Award will be disbursed based on achievement of specific Operational Milestones established by CIRM. An “Operational Milestone,” as defined in CIRM’s Award Management Policy, is an objective event that is indicative of project progress occurring as proposed in the Application. CIRM establishes Operational Milestones for inclusion in the Award based upon information provided in the Application. CIRM may consult with external advisors to inform development of Operational Milestones for the proposed research and/or access planning activities. The successful achievement of an Operational Milestone may trigger the disbursement of additional funds under the Award as scheduled in the NOA. If funds allocated to a specific Operational Milestone (including both CIRM funds and the required Applicant co-funds) are exhausted prior to achievement of that milestone, the Awardee will be responsible for covering any remaining costs. CIRM expects that the Applicant’s contingency plan will identify project timeline and budget risks and will provide details for covering such costs, including the source of funding. CIRM reserves the right to make adjustments to the timeline for inclusion in the Notice of Award to ensure that funds are appropriately dispersed across Operational Milestones. If CIRM determines, in its sole discretion, that an Awardee has failed to satisfy an Operational Milestone within four months of the date that the Operational Milestone was scheduled to have been completed, or if the delay is not addressed to CIRM’s satisfaction, CIRM may permanently cease disbursements and terminate the Award.
Suspension Events
CIRM reserves the right to hold or terminate disbursements if CIRM determines, in its sole discretion, that a Suspension Event has occurred. A “Suspension Event,” as defined in CIRM’s Award Management Policy, means a pre-defined condition that triggers a hold of CIRM funding until the Suspension Event has been resolved, if resolvable. Following a Suspension Event, the Awardee is expected to provide CIRM with a plan to resolve the issue that triggered the Suspension Event. If a Suspension Event is not resolved to CIRM’s sole satisfaction, CIRM has the right to terminate the Award. CIRM establishes Suspension Events for inclusion in the NOA based on information provided in the Application.
Strategic Planning Committee
Upon approval of an Award, CIRM will require that the Awardee assemble an independent Strategic Planning Committee (SPC) to provide expertise in clinical development, including manufacturing, regulatory and commercialization strategies. It is expected that this SPC will meet within the first quarter after Award launch and thereafter at least twice a year. All SPC meetings must be attended by the CIRM program officer and may include other CIRM staff. To ensure appropriate expertise is represented on the SPC, membership is subject to CIRM approval. Remuneration of SPC members will be considered an allowable expense from CIRM project funds. Minutes of SPC meetings must be agreed to by all SPC members and supplied to CIRM within 30 days.
Reporting
Awardees will be required to provide periodic written Progress and Financial Reports to CIRM. CIRM requires Awardees to provide clinical trial enrollee demographic data in the trial population as specified in the Application. In addition to ethnic and racial background, with further breakdowns within Asian and Pacific Islander categories pursuant to California law, CIRM asks for age (banded), annual home income (banded), insurance status, gender identity and sexual orientation. Awardees developing a therapeutic will be required to submit a Quality Target Product Profile annually and at the conclusion of the Award.
Data sharing and management
The sharing of data and knowledge produced from CIRM-Funded Projects is key to advancing the field of regenerative medicine and accelerating the discovery, validation and development of treatments for patients. CIRM requires Awardees to manage and preserve raw data, processed data, and metadata, and make applicable data and metadata available to the broader scientific community. CIRM also requires Applicants to allocate funds in their proposed budget for personnel and/or activities related to managing and sharing data produced from the funded project. Refer to CIRM Data Sharing and Management for additional information on how Applicants should address data sharing and how the data sharing overview will be evaluated. The requirements described in CIRM Data Sharing and Management are incorporated here by reference.
CIRM regulations and policies
Awards made through this Program Announcement will be subject to all applicable CIRM regulations. These regulations can be found on CIRM’s website at CIRM Stem Cell Grant Regulations.
Clinical trials
Clinical trials funded by CIRM must be listed on ClinicalTrials.gov and Awardees must submit the administrative and scientific results of the trial to the ClinicalTrials.gov results database within one year of completion of the studies (in compliance with FDAAA801), for the benefit of the field.
Resources and Contact Information
CIRM-Funded Infrastructure
CIRM has established a set of Infrastructure Programs to help CIRM Applicants and Awardees prepare competitive Applications and to accelerate development of stem cell-based and genetic therapies.
The CIRM Clinical Network is a statewide network composed of Alpha Clinics and Community Care Centers of Excellence with a common goal of streamlining and accelerating the delivery of cell and gene therapies to patients who need them. The CIRM Clinical Network supports stem cell-based and genetic therapy clinical trials for academic and commercial partners. Applicants and Awardees can partner with the CIRM Clinical Network to identify California trial sites, evaluate patient cohorts, develop trial plans and protocols, and accelerate trial initiation and completion.
The CIRM Cell and Gene Therapy Manufacturing Network is composed of nine Non-Profit Good Manufacturing Practice (GMP) facilities that are co-located with the CIRM Alpha Clinics. Applicants and Awardees can choose to utilize the Network GMP facilities for process development, manufacturing, quality control testing and other related services.
CIRM Industry Resource Partnership Program
The CIRM Industry Resource Partnership Program is composed of select contract development and manufacturing organizations (CDMOs), contract research organizations (CROs), and other vendors and service providers that are committed to making their consultations, services, and resources more accessible to CIRM-Funded Projects.
For more information about this and CIRM’s other funding programs, please visit our Current Funding Opportunities page to access Program Announcements, resources, and FAQs. For programmatic questions that are not addressed in the above resources, send email correspondence to clinical@cirm.ca.gov.
For questions related to Application review, send email correspondence to review@cirm.ca.gov.
For questions related to budgets or allowable project costs, please consult the Grants Management FAQ. For more information on budgets or allowable costs that are not addressed in the above resources, send email correspondence to grantsmanagement@cirm.ca.gov.
Terms used here are defined in CIRM Award Management Policy and CIRM Funding Opportunities: Common Requirements and Definitions.
Information about CIRM’s data sharing requirements is found in CIRM Data Sharing and Management.
Requirements and guidelines to address access planning are available in Patient Access Planning Requirements.
Consult Allowable Costs and Co-Funding FAQ for additional information to aid in budget preparation.
Recent Document Revisions
Date | List of Changes |
10/15/2026 | |
08/06/2026 | |
07/01/2026 | |
04/08/2026 | |
04/03/2026 | |
05/14/2025 | |
07/03/2024 |